VanEck Pharmaceutical ETFPPH
Type
ETF
Peer group
Global equity
Net assets
$1.3B
Expense ratio
0.36%
1-year return
+30.4%
3 years, a year
+13.8%
5 years, a year
+10.5%
12-month yield
1.96%
Holdings
26
What it aims to do.
VanEck Pharmaceutical ETF (the Fund) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (the Pharmaceutical Index or the Index).
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co | 18.70% |
| NVS Novartis AG | 10.76% |
| MRK Merck & Co Inc | 9.68% |
| PFE Pfizer Inc | 5.23% |
| NVO Novo Nordisk A/S | 4.81% |
| SNY Sanofi SA | 4.73% |
| BMY Bristol-Myers Squibb Co | 4.63% |
| GSK Gsk Plc | 4.58% |
| JOBY AstraZeneca PLC | 4.40% |
| JNJ Johnson & Johnson | 4.34% |
More on PPH.
- PPH overview
- PPH holdings
- PPH risk
- PPH costs
- PPH money in and out
- PPH share classes
- Compare PPH with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.